Answers are grounded in this paper and cite their sources.
Osteoporosis (OP) in radiographic axial spondyloarthritis (r-axSpA) exhibits a paradoxical mechanism. Chronic inflammation driven by pro-inflammatory cytokines (TNF-α, IL-17A/F, and IL-23) leads simultaneously to accelerated trabecular bone resorption with deterioration of bone microarchitecture and to pathological new bone formation (syndesmophytes, enthesophytes), which locally increases bone mineral density (BMD). As a result, standard dual-energy X-ray absorptiometry (DXA) significantly underestimates the true fracture risk, which is 2-8 times higher than in the general population. The aim of this narrative review was to discuss the pathomechanisms of OP in r-axSpA, with particular emphasis on the role of key pro-inflammatory cytokines, and to critically evaluate the rationale for using antiresorptive, biological, and anabolic therapies in the context of the specific bone pathology of this disease. The review included original research articles, systematic and narrative reviews, and guidelines published between 2015 and 2025, identified through searches in PubMed/MEDLINE, Embase, and Scopus using combinations of keywords related to r-axSpA, osteoporosis, bone microarchitecture (TBS), teriparatide, romosozumab, and inhibitors of TNF-α, IL-17, and JAK. Antiresorptive agents increase BMD but do not interrupt the cytokine-driven catabolic process in trabecular bone, which limits their ability to improve microarchitecture and reduce fracture risk. IL-17A/F inhibitors through effective control of inflammation, exert a beneficial effect on bone metabolism and may slow radiographic progression. Anabolic agents acting primarily via the Wnt/β-catenin pathway, improve not only BMD but, more importantly, bone quality and microarchitecture - making them a potentially more causal treatment option for OP in r-axSpA. Given the dominant role of microarchitectural deterioration, earlier consideration of anabolic agents may be warranted in patients with low trabecular bone score (TBS), abnormal 3D-Shaper results, or low-energy fractures - ideally combined with effective biologic control of inflammation. Prospective clinical trials evaluating this therapeutic strategy are urgently needed.
No takes yet. Share an insight, caveat, or question.
Ligocki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: